Back to top

Analyst Blog

Acorda Therapeutics, Inc. (ACOR - Analyst Report) recently announced that an additional method of use patent (US patent application no. 8,440,703) related to Ampyra twice-daily dosing of less than 15 mg has been issued by the US Patent and Trademark Office (USPTO).

We note that two method of use patents for Ampyra have already been issued by the USPTO in 2011 and 2013, which are valid till 2027 and 2026, respectively. The ‘703 method of use patent will protect Ampyra till 2025.

We remind investors that the US Food and Drug Administration (FDA) approved Ampyra in Jan 2010 for the improvement of walking in multiple sclerosis patients. Ampyra is available outside the US under the trade name Fampyra. Acorda has a license and collaboration agreement with Biogen Idec (BIIB - Analyst Report) for the development and commercialization of Fampyra outside the US.

Ampyra is being studied for other indications as well including cerebral palsy (encouraging efficacy data reported in Apr 2013 from a phase II proof-of-concept study) and post-stroke deficits (positive top-line data from a phase II proof-of-concept study reported in Apr 2013). The company plans to undertake further development of Ampyra for the post-stroke deficit indication.

We believe that approval for additional indications will boost Ampyra sales. However, we remain worried about the company’s over dependence on Ampyra for growth

Acorda carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. and Jazz Pharmaceuticals (JAZZ - Analyst Report) look attractive with both being Zacks Rank #1 (Strong Buy) stocks.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GRUPO FINAN… GGAL 17.01 +2.66%
BBVA BANCO… BFR 13.83 +2.52%
BPZ RESOURC… BPZ 3.12 +1.96%
CTPARTNERS… CTP 11.88 +1.63%
DELTA AIR L… DAL 37.45 +1.33%